Printer Friendly

KODAK, HOFFMANN-LA ROCHE AND CHIRON

 ROCHESTER, N.Y., BRANCHBURG, N.J., and EMERYVILLE, Calif., June 3 /PRNewswire/ -- Eastman Kodak Company (NYSE: EK), Hoffmann-La Roche Inc. (Roche), and Chiron Corporation (NASDAQ: CHIR) (which acquired Cetus Corporation in 1991) today announced they have reached an agreement regarding the rights to polymerase chain reaction (PCR) technology in in-vitro diagnostics. This action ends a dispute among the three companies related to ownership and rights under PCR patents.
 Roche acquired the PCR technology from Cetus in 1991. The settlement clears the way for both Kodak and Roche to market diagnostic products using this important DNA amplification process, continue development programs and to market new PCR products.
 Kodak and its affiliates receive a non-exclusive royalty-bearing license without sub-licensing rights limited to the in-vitro human diagnostics field. Kodak also acknowledges Roche as the sole owner of the key patents covering the PCR process and other defined patent properties pertaining to PCR.
 PCR technology allows very small quantities of DNA to be reproduced into quantities large enough to be detected and interpreted. It shows great promise in the early detection of cancer, infectious and genetic diseases. It can also be used to develop clear evidence in situations where the identification of human tissue is important, such as in assault and paternity disputes.
 Roche Molecular Systems, one of the three business units under the Roche Diagnostics Group umbrella, is dedicated to the worldwide development, manufacture and marketing of PCR and is currently developing the technology in a variety of different markets, including human diagnostics, research, quality control, environmental and forensics.
 Kodak is a global leader in the clinical chemistry and immunodiagnostics markets. Ektachem DT60, 250, 500, 550XRC and 750XRC analyzers provide clinical chemistry testing for low-, mid- and high- volume laboratories respectively. Kodak SureCell test kits are designed for rapid testing in physician's offices, clinics and hospitals. Kodak also makes Amerlite (NRIA) and Amerlex (RIA) immunoassay tests and systems.
 Chiron Corporation, headquartered in Emeryville, Calif., participates in global healthcare businesses in four markets: diagnostics, through its joint business with Ortho Diagnostic Systems, Inc., and Chiron Diagnostics, its emerging business in quantitative DNA/RNA probe tests; vaccines, therapeutics, and ophthalmics.
 -0- 6/3/93
 /CONTACT: Terence McArdle, 716-724-6523, or Paul C. Allen Media Relations, 716-724-5802, both of Eastman Kodak Company; or Paula Evangelista of Hoffman-La Roche Inc., 201-235-5929/
 (EK CHIR)


CO: Eastman Kodak Company; Hoffmann-La Roche Inc.; Chiron Corporation ST: New York, New Jersey, California IN: MTC SU:

AR -- CL010 -- 5049 06/03/93 14:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:412
Previous Article:COLLINS & AIKMAN HOLDINGS CORPORATION REPORTS IMPROVEMENT IN FIRST QUARTER RESULTS
Next Article:APPLIED GRAPHICS TECHNOLOGIES ESTABLISHES A NEW DIGITAL IMAGING DIVISION TAKING STATE-OF-THE-ART PHOTO CD TECHNOLOGY TO THE MARKETPLACE
Topics:


Related Articles
GENETICS INSTITUTE COMMENCES DEVELOPMENT OF NEW BLOOD CELL GROWTH AND STIMULATORY FACTOR
HOFFMANN-LA ROCHE AND ABBOTT AGREE TO LICENSE KEY PATENTS FOR DIAGNOSTIC APPLICATIONS OF GENE AMPLIFICATION TECHNOLOGIES
BIOJECT SIGNS DEVELOPMENT AGREEMENT WITH HOFFMANN-LA ROCHE
CARGILL BREAKS GROUND FOR VITAMIN E PLANT WITH HOFFMANN-LA ROCHE
HOFFMANN-LA ROCHE BECOMES FIRST TO JOIN JACKSON LABORATORY BIOINFORMATICS CONSORTIUM
PATENT AND TRADEMARK OFFICE RULES IN FAVOR OF HOFFMANN-LA ROCHE AND GENENTECH IN RECOMBINANT ALPHA INTERFERON INTERFERENCE
FDA CLEARS FIRST IMPLANT FOR CMV RETINITIS Vitrasert A New Treatment Option for People with AIDS
F. Hoffmann-La Roche and Affymetrix Sign DNA Chip Agreement for Gene Expression Monitoring
Roche Grants PCR License to Visible Genetics Inc. for DNA-Based Diagnostic Sequencing
Chiron Names Paul Hastings President of Its Biopharmaceutical Business.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters